Emerging treatments
Normocapnic hyperpnea (ClearMate™)
The ClearMate device™ accelerates elimination of CO from the blood by inducing hyperventilation by adding carbon dioxide to the breathing mix. It was approved by the Food and Drug Administration in 2019 on the basis of increased elimination of carboxyhemoglobin, versus normobaric oxygen, and a lack of device-related complications.[69][70] Whether the device is as effective as hyperbaric oxygen treatment in improving clinically-relevant outcomes is to be determined.
Use of this content is subject to our disclaimer